Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Barrio-Alonso, C; Nieto-Valle, A; Garcia-Martinez, E; Gutiérrez-Seijo, A; Parra-Blanco, V; Márquez-Rodas, I; Avilés-Izquierdo, JA; Sánchez-Mateos, P; Samaniego, R.

Chemokine profiling of melanoma-macrophage crosstalk identifies CCL8 and CCL15 as prognostic factors in cutaneous melanoma

JOURNAL OF PATHOLOGY. 2024; 262(4): 495-504 Nº de citas: 8 [doi:10.1002/path.6252]

Cohen, AT; Creeper, KJ; Alikhan, R; Er, C; Connors, JM; Huisman, MV; Munoz, A; Vescovo, G; Bauersachs, R; Ageno, W; Agnelli, G; Becattini, C.

Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

THROMBOSIS AND HAEMOSTASIS. 2024; 124(07): 676-683 Nº de citas: 4 [doi:10.1055/s-0043-1778642]

González, MM; Sanz-Pastor, AG; Gómez, RA; Torrecilla, NB; Moreno, DM; Fernández, LG; Rivas, AM; Guerra, AL; Alvarez, R; Arranz, JA; Rodas, IM; Escudero, V; Sanjurjo, M; Vallejo, JM; Martín, M; Albarrán, OG.

Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction

Endocrine Metabolic & Immune Disorders-Drug Targets. 2024; 24(14): 1628-1639 Nº de citas: 1 [doi:10.2174/0118715303280679240206100137]

Ou, SHI; Le, XN; Nagasaka, M; Reungwetwattana, T; Ahn, MJ; Lim, DW; Santos, ES; Shum, E; Lau, SC; Lee, JB; Calles, A; Wu, FY; Lopes, G; Sriuranpong, V; Tanioki, J; Horinouchi, H; Garassino, MC; Popat, S; Besse, B; Rosell, R; Soo, RA.

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

LUNG CANCER-TARGETS AND THERAPY. 2024; 15: 87-114 Nº de citas: 1 [doi:10.2147/LCTT.S463429]

Grande, E; Arranz, JA; De Santis, M; Bamias, A; Kikuchi, E; del Muro, XG; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Schutz, FA; Puente, J; Li, JR; O'Donnell, PH; Kalebasty, AR; Ye, DW; Mariathasan, S; Bene-Tchaleu, F; Bernhard, S; Lee, C; Davis, I; Galsky, M.

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

LANCET ONCOLOGY. 2024; 25(1): 29-45 Nº de citas: 29 [doi:10.1016/S1470-2045(23)00540-5]

Bamias, A; Davis, I; Galsky, M; Arranz, JA; Kikuchi, E; Grande, E; Muro, XGD; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Schutz, FA; Puente, J; Li, JR; Panni, S; Gumus, M; Oezgueroglu, M; Mariathasan, S; Poloz, Y; Bene-Tchaleu, F; Lee, C; Bernhard, S; De Santis, M.

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

LANCET ONCOLOGY. 2024; 25(1): 46-61 Nº de citas: 26 [doi:10.1016/S1470-2045(23)00539-9]

García-Sáenz, JA; Marmé, F; Untch, M; Bonnefoi, H; Kim, SB; Bear, H; Mc Carthy, N; Gelmon, K; Martin, M; Kelly, CM; Reimer, T; Toi, M; Law, E; Bhattacharyya, H; Gnant, M; Makris, A; Seiler, S; Burchardi, N; Nekljudova, V; Loibl, S; Rugo, HS.

Patient-reported outcomes in high-risk HR+ /HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

EUROPEAN JOURNAL OF CANCER. 2024; 196: 113420-113420 Nº de citas: 3 [doi:10.1016/j.ejca.2023.113420]

Munoz, AJ; Ortega, L; Gutierrez, A; Gallardo, E; Rubio-Rodriguez, D; Rubio-Terres, C; Moron, B; Garcia-Alfonso, P; Soria, JM.

Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain

Journal of Medical Economics. 2023; 26(1): 1145-1154 Nº de citas: 1 [doi:10.1080/13696998.2023.2248839]

Aparicio, I; Iranzo, P; Reyes, R; Bote, H; Saigi, M; Bringas, M; Bosch-Barrera, J; Corral, J; Aparisi, F; Ruffinelli, JC; Jimenez, B; Lage, Y; López-Castro, R; Majem, M; Vázquez, S; Artal, A; Rodríguez-Pérez, A; Lázaro-Quintela, M; Torres, JMS; Reguart, N; Cucurull, M; Gil-Bazo, I; Camps, C; Nadalj, E; del Barrio, A; Garrido, P; Dómine, M; Alvarez, R; Muñoz, AJ; Calles, A.

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

THROMBOSIS RESEARCH. 2023; 232: 133-137 Nº de citas: 3 [doi:10.1016/j.thromres.2023.11.007]

Grande, E; Bamias, A; Galsky, MD; Kikuchi, E; Davis, ID; Arranz, JA; Kalebasty, AR; del Muro, XG; Park, SH; De Giorgi, U; Alekseev, B; Mencinger, M; Izumi, K; Puente, J; Li, JR; Bernhard, S; Nicholas, A; Telliez, J; De Santis, M.

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

European Urology Open Science. 2023; 58: 28-36 [doi:10.1016/j.euros.2023.10.002]

Pfeiler, G; Hlauschek, D; Mayer, EL; Deutschmann, C; Kacerovsky-Strobl, S; Martin, M; Meisel, JL; Zdenkowski, N; Loibl, S; Balic, M; Park, H; Prat, A; Isaacs, C; Bajetta, E; Balko, JM; Bellet-Ezquerra, M; Bliss, J; Burstein, H; Cardoso, F; Fohler, H; Foukakis, T; Gelmon, KA; Goetz, M; Haddad, TC; Iwata, H; Jassem, J; Lee, SC; Linderholm, B; Los, M; Mamounas, EP; Miller, KD; Morris, PG; Munzone, E; Gal-Yam, EN; Ring, A; Shepherd, L; Singer, C; Thomssen, C; Tseng, LM; Valagussa, P; Winer, EP; Wolff, AC; Zoppoli, G; Machacek-Link, J; Schurmans, C; Huang, X; Gauthier, E; Fesl, C; Dueck, AC; DeMichele, A; Gnant, M.

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(33): 5118 Nº de citas: 22 [doi:10.1200/JCO.23.00126]

Antolín Novoa S; Escrivá-de-Romaní S; Tolosa Ortega P; Oliva Fernández L; López López R; López González A; de la Morena Barrio P; Echavarria Díaz-Guardamino I; Alés Martinez JE; Garate Z; González-Cortijo L.

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).

Cancer Treatment and Research Communications. 2023; 37: 100772-100772 Nº de citas: 2 [doi:10.1016/j.ctarc.2023.100772]

Masiá, M; de la Tabla, AGO; Gutiérrez, F.

Cancer screening in people living with HIV

Cancer Medicine. 2023; 12(21): 20590-20603 Nº de citas: 5 [doi:10.1002/cam4.6585]

Hernández, JJC; Arrula, VA; Alvarez, YE; Castaño, AG; de Castro, JJG; Docampo, LI; Sorrosal, JL; Segura, PP; Domínguez, AR; Campos-Lucas, FJ; Rodríguez, IS; Bessa, M; Gratal, P; Caballero-Martínez, F; Martín, DM; Antón-Rodríguez, C; López, R.

Indicators to evaluate quality of care in head and neck cancer in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. 2023; 26(5): 1089-1097 Nº de citas: 1 [doi:10.1007/s12094-023-03298-z]

Pascual J; Gil-Gil M; Proszek P; Zielinski C; Reay A; Ruiz-Borrego M; Cutts R; Ciruelos Gil EM; Feber A; Muñoz-Mateu M; Swift C; Bermejo B; Herranz J; Margeli Vila M; Antón A; Kahan Z; Csöszi T; Liu Y; Fernandez-Garcia D; Garcia-Murillas I; Hubank M; Turner NC; Martín M.

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.

CLINICAL CANCER RESEARCH. 2023; 29(20): 4166-4177 Nº de citas: 2 [doi:10.1158/1078-0432.CCR-23-0956]

Kumar, R; Mardones, M; Costa, L; Saini, S; Villarreal-Garza, C; Martinez-Cannon, BA; Manjunath, G; Sinha, S; Han, ZY; Arora, A; Ferreira, AM; Larsen, L; Hairabedian, S; Curry, T; Borge, H; Amorim, G; Shimizu, C; Zamre, V; Toi, M; Fisher, PB; Clarke, R; Lipton, A; Martin, M; Warner, E.

Beyond October, Beyond Pink: A Year-Round Revelation for Women's Breast Health

JOURNAL OF WOMENS HEALTH. 2023; 32(11): 1143-1146 Nº de citas: 3 [doi:10.1089/jwh.2023.0663]

Lopez-Tarruella, S; del Monte-Millan, M; Roche-Molina, M; Jerez, Y; Diaz-Guardamino, IE; López, BH; Casado, SG; Marquez-Rodas, I; Alvarez, E; Cebollero, M; Massarrah, T; Ocana, I; Arias, A; García-Sáenz, JA; Anton, FM; Garate, CO; Muñoz, DM; Marrupe, D; Alvarez, MAL; Enrech, S; Muiño, CB; Martín, M.

Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

BREAST CANCER RESEARCH AND TREATMENT. 2023; 203(1): 163-172 Nº de citas: 5 [doi:10.1007/s10549-023-07094-9]

Calles A; Arregui M; Suárez-González J; García-Martos M; Márquez-Rodas I; Álvarez R; Martin M.

Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report.

Jco Precision Oncology. 2023; 7: Nº de citas: 2 [doi:10.1200/PO.23.00321]